Innate immunity in the Guillain-Barré syndrome - Innate immunity in GBS (iGBS)

Erasmus MC, Universitair Medisch Centrum Rotterdam0 个研究点目标入组 124 人开始时间: 待定最近更新: 2024年2月28日

试验速览

暂无简介。

•Healthy controls:
•- Age 18 years or older
•- Written informed consent given by the subject
•Former GBS patients:
•- Fulfilling the diagnostic criteria for GBS (Asbury, 1990), or its variant Miller Fisher syndrome (MFS).
•- Current age 18 years or older
•- Written informed consent given by the patient;Recurrent GBS patients:
•- Occurrence of at least two episodes of GBS, as determined by the diagnostic criteria for GBS (Asbury, 1990), or its variant Miller Fisher syndrome (MFS).
•- Age 18 years
•- Written informed consent given by the patient

•Healthy controls:
•- No serological evidence for exposure to a virus, as determined by IgG serology for EBV, CMV, HEV or influenza antigens.;All groups:
•Additional diseases or disorders at time of blood sampling that may influence the endpoints:
•- autoimmune diseases (like multiple sclerosis, psoriasis, Crohn*s disease, ulcerative colitis, rheumatoid arthritis, SLE and other systemic diseases)
•- acute and chronic infectious diseases (like infectious mononucleosis, HIV/AIDS)
•- malignancies (not in remission)
•Medicines at time of blood sampling that may affect endpoints (i.e. inflammatory processes):
•- NSAIDs, oral corticosteroids, cyclosporine
•- Cytostatic compounds
•- Cytokines (analogues) and biologicals
•- Intravenous immunoglobulins.

发起方